Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: Two-year randomised trial in children from Central Europe.

Created on 10 Oct 2026

Authors

Emilia Wnękowicz-Augustyn, Edward Wylęgała, Martyna Kobielnik, Sławomir Teper

Published in

Journal of optometry. Pages 100635. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

The global increase in childhood myopia underscores the need for effective control strategies. This study evaluated the effectiveness of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine eye drops in slowing myopia progression in European children over two years.
A total of 110 Polish and Ukrainian children aged 6-16 years without significant ocular pathology were randomised to single-vision spectacles plus nightly 0.01% atropine (group A) or DIMS lenses plus nightly placebo (group B). Primary outcomes were changes in cycloplegic spherical equivalent refraction (SER) and axial length, assessed at 6-month intervals.
At 24 months, mean axial elongation was lower in group B (0.22 ± 0.22 mm) than in group A (0.32 ± 0.29 mm), particularly among children aged 6-11 years (0.30 ± 0.23 mm vs 0.48 ± 0.31 mm). Similar patterns were observed for SER progression: 0.47 ± 0.47 D in group B versus 0.70 ± 0.58 D in group A, with the greatest difference in younger children (0.59 ± 0.48 D vs 1.05 ± 0.64 D). Differences in older children were smaller.
In this study, DIMS lenses were associated with greater efficacy than 0.01% atropine in reducing myopia progression, particularly in children aged 6-11 years. Differences in adherence between the interventions should be considered when interpreting these findings. DIMS lenses may represent an effective option for myopia control in European populations.

PMID:
42855355
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement